Pipeline > APD421

Post-operative nausea & vomiting (PONV)

Description

APD421 is an intravenous formulation of a currently marketed oral drug for the new use of prevention and treatment of post-operative nausea & vomiting (PONV). The drug is a dopamine D2-antagonist and data generated by Acacia Pharma suggest that it should offer significant advantages over existing D2-antagonist anti-emetics given its therapeutic window and excellent safety profile.

Status

APD421 has been shown by Acacia Pharma to be highly effective in preclinical models of PONV. A Phase IIa clinical study to establish proof-of-concept (PoC) in cancer patients receiving the highly emetogenic chemotherapeutic agent cisplatin, was initiated Q1 2011. The PoC study was then extended during Q4 2011 to include an additional arm due to the positive results generated. A Phase II dose-ranging study in 200 post-surgical patients at risk from PONV was initiated January 2012.